Key Controversies in the Treatment of Breast Cancer

CME
This activity discusses the evidence for use of new therapeutic options alone and in combination with traditional agents, including approaches used in sequence and combination.
Duration
March 23, 2010 to March 23, 2011
Credits
Maximum of 1.0 AMA PRA Category 1 Credits™
Faculty
John K. Erban, MD | Paula D. Ryan, MD, PhD | John A. Fromson, MD

This course is not part of OncologySTAT.
By clicking the button below you will be leaving this website.


Community CommentsTotal comments to date:

Program accredited by:

The joint sponsorship of Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, Massachusetts General Hospital Academy and Reed Medical Education.

Program supported by:

Our evidence-based curriculum is supported by an educational grant from Genetech and Pfizer.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration